Coalition for Epidemic Preparedness Innovations (CEPI) is pleased to announce its third call for proposals (CfP3i) for the development of human vaccines against Rift Valley fever (RVF) and Chikungunya (CHIK) diseases. RVF disease is included among the WHO R&D Blueprint list of priority pathogens in 2018, while CHIK is deemed to present a major public health risk where further R&D is needed.
Funding will be provided by CEPI with anticipated support from the European Commission’s Horizon 2020 programme.
This call for proposals invites vaccine developers to achieve the following objectives:
For RVF vaccines: support accelerated clinical testing or activities enabling clinical testing of the most advanced RVF vaccine candidates, including identification of correlates of protection and their validation.
For CHIK vaccines: support the rapid progression of the most advanced CHIK vaccine candidates through mid-stage and late-stage clinical development, and support activities enabling future phase III testing, including identification of correlates of protection and their validation.
Significant progress of the project should be made in the 12 to 15 months after the signing of a CEPI funding agreement.
Projects must be completed within 3 years from January 2019.
A second open call (CfP3ii) is anticipated to open in 2020, which may advance work undertaken in CfP3i.
CfP3i presents a unique opportunity for CEPI and the European Commission to work in partnership to support the advancement and diversification of the current vaccine development pipeline against the RVF and CHIK.
The budget of CfP3i is USD 48 million and it is expected to fund 1 to 8 projects. Funding for pre-award costs might be provided (conditions apply; see application documents). The budget for the second open call (CfP3ii) to open in 2020 is USD 100 million.